INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 419m ago
HOUSE PTR18m ago
SEC 13F18m ago
ROBINHOOD CHAIN18m ago
SEC FORM 4/Grant or awardVerified data

Hamilton James C reported ARWR

Chief Medical Officer · ARROWHEAD PHARMACEUTICALS, INC. · Common Stock

Side
A
Value
—
Shares
75.0K
Price
—
Executed
Jan 6, 2026
Disclosed
Jan 8, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 6 executedJan 8, 2026 disclosed

ARWR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 43.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ARWR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    CG
    Cohen Matthew GregoryDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Grant or award
    		A—
    11.9K sh
    		Jun 15, 2026Jun 17, 2026
    traded Jun 15, 2026
    		+2dSEC FORM 4

    Evidence

    11
    HC
    Hamilton James CChief Medical Officer
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$750K
    10.0K sh
    		Apr 23, 2026Apr 24, 2026
    traded Apr 23, 2026
    		+1dSEC FORM 4

    Evidence

    21
    AJ
    Apel Daniel JosephChief Financial Officer
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Grant or award
    		A—
    75.0K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    15
    VV
    Vakiener VictoriaDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$359K
    5,281 sh
    		Dec 19, 2025Dec 23, 2025
    traded Dec 19, 2025
    		+4dSEC FORM 4

    Evidence

    12
    VV
    Vakiener VictoriaDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$186K
    2,799 sh
    		Dec 19, 2025Dec 23, 2025
    traded Dec 19, 2025
    		+4dSEC FORM 4

    Evidence

    12
    VV
    Vakiener VictoriaDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$134K
    1,960 sh
    		Dec 19, 2025Dec 23, 2025
    traded Dec 19, 2025
    		+4dSEC FORM 4

    Evidence

    17
    VV
    Vakiener VictoriaDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Grant or award
    		A—
    7,819 sh
    		Dec 16, 2025Dec 18, 2025
    traded Dec 16, 2025
    		+2dSEC FORM 4

    Evidence

    13
    LH
    Lu HongboDirector
    ARWRARROWHEAD PHARMACEUTICALS, INC.
    Grant or award
    		A—
    7,819 sh
    		Dec 16, 2025Dec 18, 2025
    traded Dec 16, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001830755-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 6, 2026
    Published
    Jan 8, 2026
    Ingested by INSIDER
    Nov 5, 04:23 UTC
    Last re-read
    Nov 5, 04:23 UTC

    Extracted facts

    Filer
    Hamilton James C
    Role
    Chief Medical Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    ARROWHEAD PHARMACEUTICALS, INC.
    Ticker
    ARWR
    Shares
    75.0K
    Price per share
    $0
    Execution date (reported)
    Jan 6, 2026
    Owned after transaction
    247.0K shares
    Days from execution to publication
    2

    What this establishes

    Hamilton James C filed this Form 4 reporting a grant or award of ARWR on Jan 6, 2026. It became public on Jan 8, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Hamilton James Ccik:0001830755
    Issuer
    ARROWHEAD PHARMACEUTICALS, INC.cik:0000879407

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.